CSL Ltd ( ASX: CSL) shares have faced a tough year. Whilst the broader market has extended to new highs in 2024, shares in ...

Here are a couple of strong ASX 200 shares that have been given buy ratings by brokers recently. Let's find out ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

KORU Medical Systems is poised for growth with solid revenue increases and multiple growth drivers. Find out why KRMD stock ...

Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical ...

Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.

CSL Seqirus is one of three healthcare businesses owned by the parent company. The other two are CSL Behring, focused on biotherapies and rare diseases, and CSL Vifor, focused on iron deficiency and ...

CSL Finance Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 778.37 Crore) operating in Financial Services sector. CSL Finance Ltd. key Products/Revenue Segments ...